State Street’s Benitec Biopharma BNTC Stock Holding History

State Street’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.6M	Buy	338,249 +93,198	+38%	+$1.08M	﹤0.01%	3087
2025 Q4	$3.3M	Buy	245,051 +26,653	+12%	+$369K	﹤0.01%	3160
2025 Q3	$3.06M	Buy	218,398 +57,325	+36%	+$732K	﹤0.01%	3191
2025 Q2	$1.88M	Buy	161,073 +139,883	+660%	+$1.96M	﹤0.01%	3336
2025 Q1	$276K	Buy	21,190 +5,100	+32%	+$61.7K	﹤0.01%	3749
2024 Q4	$203K	Buy	+16,090	New	+$174K	﹤0.01%	3850
2023 Q3	–	Sell	-1,261	Closed	-$5.11K	–	4564
2023 Q2	$5.11K	Hold	1,261	–	–	﹤0.01%	4663
2023 Q1	$4.5K	Hold	1,261	–	–	﹤0.01%	4771
2022 Q4	$3.64K	Hold	1,261	–	–	﹤0.01%	4841
2022 Q3	$8K	Hold	1,261	–	–	﹤0.01%	4900
2022 Q2	$25K	Hold	1,261	–	–	﹤0.01%	4850
2022 Q1	$50K	Buy	1,261 +26	+2%	+$1.08K	﹤0.01%	4790
2021 Q4	$55K	Hold	1,235	–	–	﹤0.01%	4684
2021 Q3	$75K	Hold	1,235	–	–	﹤0.01%	4600
2021 Q2	$89K	Buy	+1,235	New	+$96.6K	﹤0.01%	4382

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

State Street's BNTC Position: Q1 2026 in Review

State Street increased its Benitec Biopharma (BNTC) stake by 38% in Q1 2026, buying an estimated $1.08M and bringing the position to 338,249 shares worth $3.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3087.

State Street first reported a position in BNTC in Q2 2021 and has held it in 15 quarters since. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

State Street held 338,249 shares of Benitec Biopharma worth $3.6M as of Q1 2026.
State Street bought 93,198 Benitec Biopharma shares in Q1 2026, an estimated $1.08M.
Benitec Biopharma made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3087 holding.
State Street first reported a position in Benitec Biopharma in Q2 2021 and has held it in 15 quarters since.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.